Tiny study tests ablation for tough heart condition – but ends early

NCT ID NCT04282850

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study compared a heart ablation procedure (pulmonary vein isolation) to standard medications for managing atrial fibrillation in people with heart failure with preserved ejection fraction. Only 13 participants were enrolled before the study was terminated early. The main goal was to see if ablation could reduce the amount of time spent in atrial fibrillation and improve exercise capacity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pulmonary vein isolation (a heart ablation procedure)
What this could lead to
If successful, this could show that ablation improves exercise capacity and reduces AF burden better than medications alone for people with both atrial fibrillation and heart failure with preserved ejection fraction.
What could go wrong
This was a very small pilot study (13 participants) that was terminated early, so results are limited and may not apply to larger populations. The procedure also carries risks like bleeding, infection, or heart rhythm complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Inova Heart and Vascular Institute

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.